FY2025 EPS Estimates for REGENXBIO Decreased by Analyst

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Analysts at Chardan Capital decreased their FY2025 earnings estimates for shares of REGENXBIO in a research note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now forecasts that the biotechnology company will post earnings of ($3.03) per share for the year, down from their prior estimate of ($1.39). Chardan Capital currently has a "Buy" rating and a $52.00 price target on the stock. The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Chardan Capital also issued estimates for REGENXBIO's FY2026 earnings at $4.87 EPS.

Other equities analysts also recently issued research reports about the stock. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a report on Tuesday, March 18th. Royal Bank of Canada reissued an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Raymond James began coverage on REGENXBIO in a report on Friday, February 7th. They set an "outperform" rating and a $27.00 target price for the company. StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Finally, HC Wainwright decreased their price target on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $32.78.

Remove Ads

REGENXBIO Stock Performance

NASDAQ:RGNX traded down $0.88 during trading hours on Thursday, reaching $6.95. The company's stock had a trading volume of 352,565 shares, compared to its average volume of 964,508. The company has a market capitalization of $348.10 million, a P/E ratio of -1.38 and a beta of 1.35. The stock has a 50 day moving average price of $7.40 and a two-hundred day moving average price of $8.74. REGENXBIO has a 12 month low of $5.62 and a 12 month high of $21.57.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.

Institutional Trading of REGENXBIO

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the period. Millennium Management LLC boosted its holdings in REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock worth $10,222,000 after purchasing an additional 1,061,187 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in REGENXBIO during the fourth quarter worth $3,865,000. Norges Bank acquired a new position in REGENXBIO during the fourth quarter worth $3,474,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of REGENXBIO in the fourth quarter worth about $2,793,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.